Sequence information
DRAVP ID DRAVPc042
Name Meplazumab
Sequence Not available
Molecular Formula Not Available
Condition/Disease COVID-19
Group Investigational
Type Antibody
Description Meplazumab is an anti-CD147 antibody, which is a recepor on host cells for viruses such as SARS-CoV2. Meplazumab's inhibition of CD147 binding to the spike proteins of viruses is thought to inhibit their entry.It is investigated as an add-on therapy in patients with COVID-19 pneumonia.
Active sequence/Structure
External Links
DrugBank Accession Number DB16465
Pubchem ID 405560467
CHEMBL ID Not Available
UNII 0EL07E29VQ
CAS Not Available
ClinicalTrails Information
| NCT Number | Study Title | Condition/Disease | Status | Phase | Sponsor |
|---|---|---|---|---|---|
| NCT04275245 | Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia | Coronavirus Disease 2019 (COVID-19) | Completed | Phase 1, 2 | Tang-Du Hospital |
| NCT05679492 | Study on the Safety and Efficacy of Meplazumab for Injection Patients COVID-19 | COVID-19 | Not yet recruiting | Phase 3 | Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd |
| NCT05679479 | Study on the Safety and Efficacy of Meplazumab for Injection in Severe Patients With COVID-19 | COVID-19 | Not yet recruiting | Phase 3 | Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd |
| NCT05113784 | the Safety and Efficacy of Meplazumab in Patients With COVID-19 | COVID-19 | Not yet recruiting | Phase 2, 3 | Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd |
